Centre for Psychiatry Research, Department of Clinical Neuroscience, Karolinska Institutet and Stockholm Health Care Services, Region Stockholm, Stockholm, Sweden.
Neurobiology Research Unit, Copenhagen University Hospital, Rigshospitalet, Copenhagen, Denmark.
Mol Psychiatry. 2022 Feb;27(2):1233-1240. doi: 10.1038/s41380-021-01349-x. Epub 2021 Nov 10.
Pharmacological and genetic evidence support a role for an involvement of the dopamine D2-receptor (D2-R) in the pathophysiology of schizophrenia. Previous molecular imaging studies have suggested lower levels of D2-R in thalamus, but results are inconclusive. The objective of the present study was to use improved methodology to compare D2-R density in whole thalamus and thalamic subregions between first-episode psychosis patients and healthy controls. Differences in thalamocortical connectivity was explored based on the D2-R results. 19 antipsychotic-naive first-episode psychosis patients and 19 age- and sex-matched healthy controls were examined using high-resolution Positron Emission Tomography (PET) and the high-affinity D2-R radioligand [C]FLB457. The main outcome was D2-R binding potential (BP) in thalamus, and it was predicted that patients would have lower binding. Diffusion tensor imaging (DTI) was performed in a subgroup of 11 patients and 15 controls. D2-R binding in whole thalamus was lower in patients compared with controls (Cohen's dz = -0.479, p = 0.026, Bayes Factor (BF) > 4). Among subregions, lower BP was observed in the ROI representing thalamic connectivity to the frontal cortex (Cohen's dz = -0.527, p = 0.017, BF > 6). A meta-analysis, including the sample of this study, confirmed significantly lower thalamic D2-R availability in patients. Exploratory analyses suggested that patients had lower fractional anisotropy values compared with controls (Cohen's d = -0.692, p = 0.036) in the inferior thalamic radiation. The findings support the hypothesis of a dysregulation of thalamic dopaminergic neurotransmission in schizophrenia, and it is hypothesized that this could underlie a disturbance of thalamocortical connectivity.
药理学和遗传学证据支持多巴胺 D2 受体(D2-R)参与精神分裂症的病理生理学。先前的分子影像学研究表明,丘脑的 D2-R 水平较低,但结果尚无定论。本研究的目的是使用改进的方法来比较首发精神病患者和健康对照者全丘脑和丘脑亚区的 D2-R 密度。根据 D2-R 结果探讨了丘脑皮质连接的差异。使用高分辨率正电子发射断层扫描(PET)和高亲和力 D2-R 放射性配体 [C]FLB457 检查了 19 名抗精神病药物初发精神分裂症患者和 19 名年龄和性别匹配的健康对照者。主要结果是丘脑的 D2-R 结合潜能(BP),预计患者的结合会降低。在 11 名患者和 15 名对照者的亚组中进行了弥散张量成像(DTI)。与对照组相比,患者的全丘脑 D2-R 结合降低(Cohen's dz=-0.479,p=0.026,贝叶斯因子(BF)>4)。在亚区中,与额叶皮质连接的丘脑 ROI 中的 BP 较低(Cohen's dz=-0.527,p=0.017,BF>6)。包括本研究样本在内的一项荟萃分析证实,患者的丘脑 D2-R 可用性明显降低。探索性分析表明,与对照组相比,患者的下丘脑辐射的各向异性分数值较低(Cohen's d=-0.692,p=0.036)。研究结果支持了精神分裂症中丘脑多巴胺能神经传递失调的假说,并且假设这可能是丘脑皮质连接紊乱的基础。